Evaluation of Amyloid Imaging in Patients with Parkinson's disease

Evaluation of Amyloid Imaging in Patients with Parkinson's disease - Evaluation of Amyloid Imaging in Parkinson's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018035

Enrollment

100

Registered

2015-06-23

Start date

2015-06-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study population consists of patients with PD, who are recruited in Keio Parkinson's Disease Database. All patients must be more than MMSE 26.

Exclusion criteria

Exclusion criteria: disaggrement

Design outcomes

Primary

Measure	Time frame
Parkinson disease who have abnormal metabolism on positive amyloid PET (stage 2 preclinical AD) and those who have abnormal metabolism on an FDG-PET scan and normal amyloid PET (which may represent non-preclinical AD but suggest other neurological disease) will be monitored for a long term to assess changes in clinical features and cognitive function over time.	—

Countries

Japan

Contacts

Public ContactDaisuke Ito

Keio University School of Medicine Department of Neurology,

d-ito@jk9.so-net.ne.jp03-5363-3788

Outcome results